ArticleThe Journal of nutrition2026
Riboflavin Deficiency Is Highly Prevalent in Females and Children across High and Low/Middle Income Countries Worldwide.
Article in The Journal of nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
27 authors.
Funding
Abstract
backgroundRiboflavin, as flavin mononucleotide and flavin adenine dinucleotide, is essential for numerous metabolic pathways. However, the prevalence of riboflavin deficiency worldwide remains unclear, because status biomarkers are very rarely measured in human studies.
objectivesThis study aimed to investigate riboflavin status in females of reproductive age and children from several regions of the world, representing both high-income countries and low/middle-income countries (HICs and LMICs).
methodsWe measured riboflavin status in population-representative samples from Ireland, United Kingdom, Cambodia, and Democratic Republic of the Congo, and in cohort samples from HICs (Northern Ireland, Spain, Canada) and LMICs (Malaysia, Lao People's Democratic Republic, Cambodia, Uganda) using the functional assay, erythrocyte glutathione reductase activation coefficient (EGRac), with higher values indicating lower status and EGRac ≥ 1.40 indicative of deficiency.
resultsIn Irish (n = 251) and British (n = 163) populations, among unsupplemented females of 18-45 y, median (95% confidence interval) EGRac values were 1.39 (1.36, 1.42) and 1.40 (1.36, 1.49), and 48% and 50%, respectively, had riboflavin deficiency. In Irish females, biomarker status declined progressively(P < 0.002) with decreasing quintiles of dietary riboflavin intakes, from >2.1 in Q1 to <1.1 mg/d in Q5.. Females in LMICs had much higher rates of riboflavin deficiency: Malaysia (72%); Cambodia (82%); and Uganda (90%). In British children (n = 307), riboflavin status declined markedly with age, with median EGRac values of 1.25 (1.20, 1.28) at age 1-5 y compared with 1.40 (1.35, 1.44) at 15-17 y. In children from LMICs, 39%-75% had riboflavin deficiency, and in Ugandan children aged 5-17 y, median EGRac was 1.77 (1.39, 2.15), corresponding with clinical deficiency signs observed in this cohort.
conclusionsRiboflavin deficiency is highly prevalent in females and children across many regions worldwide. Given the wide-ranging adverse health consequences of deficiency, population-based strategies to improve riboflavin status in both LMICs and HICs are urgently needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.